Xueping Huang
Biography
Xueping Huang, an associate chief physician at Fujian Provincial Hospital's Gastroenterology Department, graduated from Sun Yat - sen University. Academically, she serves as the deputy leader of the Fujian Digestive Diseases Society's Youth Committee, Helicobacter pylori Study Group, and is a member of the Digestive Oncology Study Group. She focuses on nurturing young talents and driving academic exchanges.
Research Interest
Huang has led and participated in multiple projects funded by the Fujian Provincial Natural Science Foundation and the Fujian Health Commission's Youth Fund. She made breakthroughs in Helicobacter pylori culture and drug - sensitivity testing, optimizing treatment regimens. Her work on hepatitis B - related liver cancer immunotherapy offers new clinical insights, and she proposed AI - assisted diagnostic methods for digestive tract tumors. She has published many high - quality SCI papers. Her Helicobacter pylori research was presented at the DDW 2024, APDW 2024, and the 2018 World Congress of Gastroenterology, winning acclaim from international experts.
Abstract
Series of Clinical Studies on the Eradication of Helicobacter pylori with the Potassium - competitive Acid Blocker- Amoxicillin Dual - Therapy Regimen
In recent years, the Potassium - competitive acid blocker(P-CABs) - amoxicillin dual - therapy regimen has been recommended for the eradication of Helicobacter pylori(H.pylori). However, there are still uncertainties about the optimal drug dosage and treatment duration. Our research group carried out a series of multi - center clinical studies in Fujian Province, China, aiming to explore the efficacy and safety of this dual - therapy regimen for H.pylori eradication. The study covered different treatment durations (7 - day, 10 - day, and 14 - day), various types of P-CABs (vonoprazan, tegoprazan, and keprazan), and different dosages of P-CABs. The results demonstrated that the 10 - day and 14 - day dual - therapy regimens outperformed the 7 - day one, and the 10 - day regimen was non - inferior to the 14 - day one. Moreover, all dual - therapy regimens with different P-CABs achieved an eradication rate of over 90%, and the low - dose P-CABs-amoxicillin dual - therapy regimen was as effective as the high - dose one. These findings hold significant implications. In China, they can directly guide clinicians in Fujian and other regions to select more appropriate treatment options for H.pylori eradication, potentially improving the overall treatment efficiency and reducing unnecessary medical costs. On a global scale, considering the high prevalence of H.pylori infection worldwide, our research provides valuable references for international medical communities. It offers a new perspective on optimizing the P-CABs - amoxicillin dual - therapy regimen, which may contribute to the development of more standardized and effective treatment strategies for H.pylori eradication globally.
